Department of Endocrinology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Sophie Howarth in
Google Scholar
PubMed
Search for other papers by Luca Giovanelli in
Google Scholar
PubMed
Search for other papers by Catherine Napier in
Google Scholar
PubMed
Department of Endocrinology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Simon H Pearce in
Google Scholar
PubMed
loss, hypoglycaemia and fatigue. Historically, the symptomatic phase was felt to be a point of no return for Addison’s patients, with a lifelong requirement for steroid replacement to avoid fatal adrenal crisis. However, a growing body of evidence
Search for other papers by Natacha Driessens in
Google Scholar
PubMed
Search for other papers by Madhu Prasai in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Christophe De Block in
Google Scholar
PubMed
Search for other papers by Eva Van Caenegem in
Google Scholar
PubMed
Search for other papers by Guy T’Sjoen in
Google Scholar
PubMed
Search for other papers by Frank Nobels in
Google Scholar
PubMed
Search for other papers by Christophe Ghys in
Google Scholar
PubMed
Search for other papers by Laurent Vroonen in
Google Scholar
PubMed
Search for other papers by Corinne Jonas in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
gastrointestinal symptoms. Hypotension was reported in 58% of cases, electrolyte disturbance in 46% and hypoglycaemia in 10%. Excluding patients younger than 18, median BMI at diagnosis was 23.5 kg/m² (IQR 20.1–27.0; min–max 14.5–43.8; n = 127). Figure 1